カテゴリー： Market Monitor Global, 世界, 医療/バイオ

慢性閉塞性肺疾患治療薬の世界市場見通し2023年-2029年

◆英語タイトル：Chronic Obstructive Pulmonary Disease Treatment Drug Market, Global Outlook and Forecast 2023-2029

Market Monitor Globalが発行した調査報告書（MMG23FB2171）

◆商品コード：MMG23FB2171
◆発行会社（リサーチ会社）：Market Monitor Global
◆発行日：2023年2月
◆ページ数：66
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後2-3営業日）
◆調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
◆産業分野：医療

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,250 ⇒換算￥494,000	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD4,225 ⇒換算￥642,200	見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）	USD4,875 ⇒換算￥741,000	見積依頼/購入/質問フォーム

★Market Monitor Globalに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

当調査レポートは次の情報を含め、世界の慢性閉塞性肺疾患治療薬市場規模と予測を収録しています。・世界の慢性閉塞性肺疾患治療薬市場：売上、2018年-2023年、2024年-2029年
・世界の慢性閉塞性肺疾患治療薬市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の慢性閉塞性肺疾患治療薬市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「気管支拡張薬」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

慢性閉塞性肺疾患治療薬のグローバル主要企業は、GSK、Novartis、Merck、Abbott、Boehringer Ingelheim、AstraZeneca、Roche、Teva、Vectura、Pfizer、Mylan、Allergan、Cipla、Akornなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL（MMG）は、慢性閉塞性肺疾患治療薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界の慢性閉塞性肺疾患治療薬市場：タイプ別、2018年-2023年、2024年-2029年
世界の慢性閉塞性肺疾患治療薬市場：タイプ別市場シェア、2022年
・気管支拡張薬、PDE-4阻害薬、ステロイド、その他

世界の慢性閉塞性肺疾患治療薬市場：用途別、2018年-2023年、2024年-2029年
世界の慢性閉塞性肺疾患治療薬市場：用途別市場シェア、2022年
・病院、診療所、その他

世界の慢性閉塞性肺疾患治療薬市場：地域・国別、2018年-2023年、2024年-2029年
世界の慢性閉塞性肺疾患治療薬市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業における慢性閉塞性肺疾患治療薬のグローバル売上、2018年-2023年
・主要企業における慢性閉塞性肺疾患治療薬のグローバル売上シェア、2022年
・主要企業における慢性閉塞性肺疾患治療薬のグローバル販売量、2018年-2023年
・主要企業における慢性閉塞性肺疾患治療薬のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
GSK、Novartis、Merck、Abbott、Boehringer Ingelheim、AstraZeneca、Roche、Teva、Vectura、Pfizer、Mylan、Allergan、Cipla、Akorn

*************************************************************

・調査・分析レポートの概要
慢性閉塞性肺疾患治療薬市場の定義
市場セグメント
世界の慢性閉塞性肺疾患治療薬市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の慢性閉塞性肺疾患治療薬市場規模
世界の慢性閉塞性肺疾患治療薬市場規模：2022年 VS 2029年
世界の慢性閉塞性肺疾患治療薬市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの慢性閉塞性肺疾患治療薬の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の慢性閉塞性肺疾患治療薬製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：気管支拡張薬、PDE-4阻害薬、ステロイド、その他
慢性閉塞性肺疾患治療薬のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：病院、診療所、その他
慢性閉塞性肺疾患治療薬の用途別グローバル売上・予測

・地域別市場分析
地域別慢性閉塞性肺疾患治療薬市場規模 2022年と2029年
地域別慢性閉塞性肺疾患治療薬売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど）
GSK、Novartis、Merck、Abbott、Boehringer Ingelheim、AstraZeneca、Roche、Teva、Vectura、Pfizer、Mylan、Allergan、Cipla、Akorn
...

This report aims to provide a comprehensive presentation of the global market for Chronic Obstructive Pulmonary Disease Treatment Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chronic Obstructive Pulmonary Disease Treatment Drug. This report contains market size and forecasts of Chronic Obstructive Pulmonary Disease Treatment Drug in global, including the following market information:
Global Chronic Obstructive Pulmonary Disease Treatment Drug Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Chronic Obstructive Pulmonary Disease Treatment Drug market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Bronchodilators Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Chronic Obstructive Pulmonary Disease Treatment Drug include GSK, Novartis, Merck, Abbott, Boehringer Ingelheim, AstraZeneca, Roche, Teva and Vectura, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Chronic Obstructive Pulmonary Disease Treatment Drug companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
[Total Market by Segment]
Global Chronic Obstructive Pulmonary Disease Treatment Drug Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Chronic Obstructive Pulmonary Disease Treatment Drug Market Segment Percentages, by Type, 2022 (%)
Bronchodilators
PDE-4 Inhibitors
Steroids
Others
Global Chronic Obstructive Pulmonary Disease Treatment Drug Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Chronic Obstructive Pulmonary Disease Treatment Drug Market Segment Percentages, by Application, 2022 (%)
Hospital
Clinic
Others
Global Chronic Obstructive Pulmonary Disease Treatment Drug Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Chronic Obstructive Pulmonary Disease Treatment Drug Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Chronic Obstructive Pulmonary Disease Treatment Drug revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Chronic Obstructive Pulmonary Disease Treatment Drug revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
GSK
Novartis
Merck
Abbott
Boehringer Ingelheim
AstraZeneca
Roche
Teva
Vectura
Pfizer
Mylan
Allergan
Cipla
Akorn
Outline of Major Chapters:
Chapter 1: Introduces the definition of Chronic Obstructive Pulmonary Disease Treatment Drug, market overview.
Chapter 2: Global Chronic Obstructive Pulmonary Disease Treatment Drug market size in revenue.
Chapter 3: Detailed analysis of Chronic Obstructive Pulmonary Disease Treatment Drug company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Chronic Obstructive Pulmonary Disease Treatment Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Chronic Obstructive Pulmonary Disease Treatment Drug Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Chronic Obstructive Pulmonary Disease Treatment Drug Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Chronic Obstructive Pulmonary Disease Treatment Drug Overall Market Size
2.1 Global Chronic Obstructive Pulmonary Disease Treatment Drug Market Size: 2022 VS 2029
2.2 Global Chronic Obstructive Pulmonary Disease Treatment Drug Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Chronic Obstructive Pulmonary Disease Treatment Drug Players in Global Market
3.2 Top Global Chronic Obstructive Pulmonary Disease Treatment Drug Companies Ranked by Revenue
3.3 Global Chronic Obstructive Pulmonary Disease Treatment Drug Revenue by Companies
3.4 Top 3 and Top 5 Chronic Obstructive Pulmonary Disease Treatment Drug Companies in Global Market, by Revenue in 2022
3.5 Global Companies Chronic Obstructive Pulmonary Disease Treatment Drug Product Type
3.6 Tier 1, Tier 2 and Tier 3 Chronic Obstructive Pulmonary Disease Treatment Drug Players in Global Market
3.6.1 List of Global Tier 1 Chronic Obstructive Pulmonary Disease Treatment Drug Companies
3.6.2 List of Global Tier 2 and Tier 3 Chronic Obstructive Pulmonary Disease Treatment Drug Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Chronic Obstructive Pulmonary Disease Treatment Drug Market Size Markets, 2022 & 2029
4.1.2 Bronchodilators
4.1.3 PDE-4 Inhibitors
4.1.4 Steroids
4.1.5 Others
4.2 By Type – Global Chronic Obstructive Pulmonary Disease Treatment Drug Revenue & Forecasts
4.2.1 By Type – Global Chronic Obstructive Pulmonary Disease Treatment Drug Revenue, 2018-2023
4.2.2 By Type – Global Chronic Obstructive Pulmonary Disease Treatment Drug Revenue, 2024-2029
4.2.3 By Type – Global Chronic Obstructive Pulmonary Disease Treatment Drug Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Chronic Obstructive Pulmonary Disease Treatment Drug Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Clinic
5.1.4 Others
5.2 By Application – Global Chronic Obstructive Pulmonary Disease Treatment Drug Revenue & Forecasts
5.2.1 By Application – Global Chronic Obstructive Pulmonary Disease Treatment Drug Revenue, 2018-2023
5.2.2 By Application – Global Chronic Obstructive Pulmonary Disease Treatment Drug Revenue, 2024-2029
5.2.3 By Application – Global Chronic Obstructive Pulmonary Disease Treatment Drug Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Chronic Obstructive Pulmonary Disease Treatment Drug Market Size, 2022 & 2029
6.2 By Region – Global Chronic Obstructive Pulmonary Disease Treatment Drug Revenue & Forecasts
6.2.1 By Region – Global Chronic Obstructive Pulmonary Disease Treatment Drug Revenue, 2018-2023
6.2.2 By Region – Global Chronic Obstructive Pulmonary Disease Treatment Drug Revenue, 2024-2029
6.2.3 By Region – Global Chronic Obstructive Pulmonary Disease Treatment Drug Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Chronic Obstructive Pulmonary Disease Treatment Drug Revenue, 2018-2029
6.3.2 US Chronic Obstructive Pulmonary Disease Treatment Drug Market Size, 2018-2029
6.3.3 Canada Chronic Obstructive Pulmonary Disease Treatment Drug Market Size, 2018-2029
6.3.4 Mexico Chronic Obstructive Pulmonary Disease Treatment Drug Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Chronic Obstructive Pulmonary Disease Treatment Drug Revenue, 2018-2029
6.4.2 Germany Chronic Obstructive Pulmonary Disease Treatment Drug Market Size, 2018-2029
6.4.3 France Chronic Obstructive Pulmonary Disease Treatment Drug Market Size, 2018-2029
6.4.4 U.K. Chronic Obstructive Pulmonary Disease Treatment Drug Market Size, 2018-2029
6.4.5 Italy Chronic Obstructive Pulmonary Disease Treatment Drug Market Size, 2018-2029
6.4.6 Russia Chronic Obstructive Pulmonary Disease Treatment Drug Market Size, 2018-2029
6.4.7 Nordic Countries Chronic Obstructive Pulmonary Disease Treatment Drug Market Size, 2018-2029
6.4.8 Benelux Chronic Obstructive Pulmonary Disease Treatment Drug Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Chronic Obstructive Pulmonary Disease Treatment Drug Revenue, 2018-2029
6.5.2 China Chronic Obstructive Pulmonary Disease Treatment Drug Market Size, 2018-2029
6.5.3 Japan Chronic Obstructive Pulmonary Disease Treatment Drug Market Size, 2018-2029
6.5.4 South Korea Chronic Obstructive Pulmonary Disease Treatment Drug Market Size, 2018-2029
6.5.5 Southeast Asia Chronic Obstructive Pulmonary Disease Treatment Drug Market Size, 2018-2029
6.5.6 India Chronic Obstructive Pulmonary Disease Treatment Drug Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Chronic Obstructive Pulmonary Disease Treatment Drug Revenue, 2018-2029
6.6.2 Brazil Chronic Obstructive Pulmonary Disease Treatment Drug Market Size, 2018-2029
6.6.3 Argentina Chronic Obstructive Pulmonary Disease Treatment Drug Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Chronic Obstructive Pulmonary Disease Treatment Drug Revenue, 2018-2029
6.7.2 Turkey Chronic Obstructive Pulmonary Disease Treatment Drug Market Size, 2018-2029
6.7.3 Israel Chronic Obstructive Pulmonary Disease Treatment Drug Market Size, 2018-2029
6.7.4 Saudi Arabia Chronic Obstructive Pulmonary Disease Treatment Drug Market Size, 2018-2029
6.7.5 UAE Chronic Obstructive Pulmonary Disease Treatment Drug Market Size, 2018-2029
7 Chronic Obstructive Pulmonary Disease Treatment Drug Companies Profiles
7.1 GSK
7.1.1 GSK Company Summary
7.1.2 GSK Business Overview
7.1.3 GSK Chronic Obstructive Pulmonary Disease Treatment Drug Major Product Offerings
7.1.4 GSK Chronic Obstructive Pulmonary Disease Treatment Drug Revenue in Global Market (2018-2023)
7.1.5 GSK Key News & Latest Developments
7.2 Novartis
7.2.1 Novartis Company Summary
7.2.2 Novartis Business Overview
7.2.3 Novartis Chronic Obstructive Pulmonary Disease Treatment Drug Major Product Offerings
7.2.4 Novartis Chronic Obstructive Pulmonary Disease Treatment Drug Revenue in Global Market (2018-2023)
7.2.5 Novartis Key News & Latest Developments
7.3 Merck
7.3.1 Merck Company Summary
7.3.2 Merck Business Overview
7.3.3 Merck Chronic Obstructive Pulmonary Disease Treatment Drug Major Product Offerings
7.3.4 Merck Chronic Obstructive Pulmonary Disease Treatment Drug Revenue in Global Market (2018-2023)
7.3.5 Merck Key News & Latest Developments
7.4 Abbott
7.4.1 Abbott Company Summary
7.4.2 Abbott Business Overview
7.4.3 Abbott Chronic Obstructive Pulmonary Disease Treatment Drug Major Product Offerings
7.4.4 Abbott Chronic Obstructive Pulmonary Disease Treatment Drug Revenue in Global Market (2018-2023)
7.4.5 Abbott Key News & Latest Developments
7.5 Boehringer Ingelheim
7.5.1 Boehringer Ingelheim Company Summary
7.5.2 Boehringer Ingelheim Business Overview
7.5.3 Boehringer Ingelheim Chronic Obstructive Pulmonary Disease Treatment Drug Major Product Offerings
7.5.4 Boehringer Ingelheim Chronic Obstructive Pulmonary Disease Treatment Drug Revenue in Global Market (2018-2023)
7.5.5 Boehringer Ingelheim Key News & Latest Developments
7.6 AstraZeneca
7.6.1 AstraZeneca Company Summary
7.6.2 AstraZeneca Business Overview
7.6.3 AstraZeneca Chronic Obstructive Pulmonary Disease Treatment Drug Major Product Offerings
7.6.4 AstraZeneca Chronic Obstructive Pulmonary Disease Treatment Drug Revenue in Global Market (2018-2023)
7.6.5 AstraZeneca Key News & Latest Developments
7.7 Roche
7.7.1 Roche Company Summary
7.7.2 Roche Business Overview
7.7.3 Roche Chronic Obstructive Pulmonary Disease Treatment Drug Major Product Offerings
7.7.4 Roche Chronic Obstructive Pulmonary Disease Treatment Drug Revenue in Global Market (2018-2023)
7.7.5 Roche Key News & Latest Developments
7.8 Teva
7.8.1 Teva Company Summary
7.8.2 Teva Business Overview
7.8.3 Teva Chronic Obstructive Pulmonary Disease Treatment Drug Major Product Offerings
7.8.4 Teva Chronic Obstructive Pulmonary Disease Treatment Drug Revenue in Global Market (2018-2023)
7.8.5 Teva Key News & Latest Developments
7.9 Vectura
7.9.1 Vectura Company Summary
7.9.2 Vectura Business Overview
7.9.3 Vectura Chronic Obstructive Pulmonary Disease Treatment Drug Major Product Offerings
7.9.4 Vectura Chronic Obstructive Pulmonary Disease Treatment Drug Revenue in Global Market (2018-2023)
7.9.5 Vectura Key News & Latest Developments
7.10 Pfizer
7.10.1 Pfizer Company Summary
7.10.2 Pfizer Business Overview
7.10.3 Pfizer Chronic Obstructive Pulmonary Disease Treatment Drug Major Product Offerings
7.10.4 Pfizer Chronic Obstructive Pulmonary Disease Treatment Drug Revenue in Global Market (2018-2023)
7.10.5 Pfizer Key News & Latest Developments
7.11 Mylan
7.11.1 Mylan Company Summary
7.11.2 Mylan Business Overview
7.11.3 Mylan Chronic Obstructive Pulmonary Disease Treatment Drug Major Product Offerings
7.11.4 Mylan Chronic Obstructive Pulmonary Disease Treatment Drug Revenue in Global Market (2018-2023)
7.11.5 Mylan Key News & Latest Developments
7.12 Allergan
7.12.1 Allergan Company Summary
7.12.2 Allergan Business Overview
7.12.3 Allergan Chronic Obstructive Pulmonary Disease Treatment Drug Major Product Offerings
7.12.4 Allergan Chronic Obstructive Pulmonary Disease Treatment Drug Revenue in Global Market (2018-2023)
7.12.5 Allergan Key News & Latest Developments
7.13 Cipla
7.13.1 Cipla Company Summary
7.13.2 Cipla Business Overview
7.13.3 Cipla Chronic Obstructive Pulmonary Disease Treatment Drug Major Product Offerings
7.13.4 Cipla Chronic Obstructive Pulmonary Disease Treatment Drug Revenue in Global Market (2018-2023)
7.13.5 Cipla Key News & Latest Developments
7.14 Akorn
7.14.1 Akorn Company Summary
7.14.2 Akorn Business Overview
7.14.3 Akorn Chronic Obstructive Pulmonary Disease Treatment Drug Major Product Offerings
7.14.4 Akorn Chronic Obstructive Pulmonary Disease Treatment Drug Revenue in Global Market (2018-2023)
7.14.5 Akorn Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 慢性閉塞性肺疾患治療薬の世界市場見通し2023年-2029年(Chronic Obstructive Pulmonary Disease Treatment Drug Market, Global Outlook and Forecast 2023-2029)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

慢性閉塞性肺疾患治療薬の世界市場見通し2023年-2029年

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp